URGN: UroGen Pharma Ltd.
Performance
URGN +13.21%
Watchlist
Select an item
Summary
URGN at a glance
URGN returned +13.21% over the past year and +7.62% a year over five years. Its worst drop in that year was -50.79%, smaller than 22% of stocks on Redstone, and its Sharpe ratio of 0.45 beats 48% of stocks on Redstone. It pays no dividends.
Current Drawdown
-47.68%
Rolling Volatility
77.68%
Actions
Metrics
Risk Indicators
Alpha15.16%
Beta1.33x
Sharpe0.45
Sortino0.65
Omega1.08
Calmar0.26
Martin1.26
Profile
About URGN
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.3B
- Listed
- May 2017
- Employees
- 291
- Headquarters
- Ra'anana, L3
- Website
- urogen.com
Comparisons